Patient Power®
Get Email Alerts!
Health Topics
Prostate Cancer Health Center
Health Center Home Audio Programs Videos Advanced Prostate Cancer
Search by Keyword:
Search by Health Topic:
View all Health Topics >
7/3/12

Prostate Cancer Prevention: The Role of PSA Testing, Biopsies and Newer Screening Techniques

The value of the PSA test has been brought under question by an advisory panel in the United States, but for the time being, there are few options for prostate cancer screening. Dr. William Catalona, a pioneer in developing the PSA test, stresses its continued importance, even when considering its imperfections. He also discusses newer tests that are becoming available to confirm a prostate cancer diagnosis that may help reduce the need for biopsies including a Magnetic Resonance Imaging (MRI) technique, the Pro-PSA blood test (recently approved in the European Union) and the new PCA3 urine test, now approved by the FDA.

Health Topics: Prostate Cancer

Get Email Updates:

Get updated automatically when new content about Prostate Cancer has been posted.
Privacy Policy
Prostate Cancer

Experts & Guests

William Catalona, M.D. William Catalona, M.D.
Director of the Clinical Prostate Cancer Screening Program, Northwestern Memorial Hospital
William J. Catalona, MD, is the director of the Clinical Prostate Cancer Program for the Robert H. Lurie Comprehensive Cancer Center of Northwestern University at Northwestern Memorial Hospital. He is professor of Urology at Northwestern University’s Feinberg School of Medicine. In addition, Dr. Catalona serves as the Medical Director of the Urological Research Foundation. He is most widely known for... more >

Transcript

  1. The Role of PSA Testing, Biopsies and Newer Screening Techniques

Related Programs

Dr. Leonard Gomella explains PSA Velocity, a term to describe the way physicians track a man's PSA levels over time.

Watch Now
Dr. Leonard Gomella responds to a recent US government panel recommendation suggesting discontinuation of the PSA test to detect prostate cancer, a recommendation which he believes could be “devastating."

Watch Now
Dr. Daniel Lin, a urologic oncologist from Seattle Cancer Care Alliance, responds to a recent government panel recommendation that healthy men should no longer be screened for prostate cancer using the prostate-specific antigen (PSA) test. Dr. Lin explains that while he feels that portions of the panel's report have merit, he believes the PSA recommendation was premature and that the decision to screen should be approached on an individual basis.

Watch Now